Toll Free: 1-888-928-9744

Peptic Ulcers - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 58 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Peptic Ulcers - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peptic Ulcers - Pipeline Review, H2 2016, provides an overview of the Peptic Ulcers (Gastrointestinal) pipeline landscape.

Peptic ulcers are open sores that develop on the inside lining of esophagus, stomach and the upper portion of small intestine. Symptoms include nausea or vomiting, unexplained weight loss, appetite changes and abdominal pain. Risk factors include smoking and alcoholism. Treatment includes antibiotic, acid blockers, antacids and proton pump inhibitors. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peptic Ulcers - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Peptic Ulcers (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peptic Ulcers (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Peptic Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 3 and 11 respectively.

Peptic Ulcers (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Peptic Ulcers (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Peptic Ulcers (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peptic Ulcers (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peptic Ulcers (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Peptic Ulcers (Gastrointestinal)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peptic Ulcers (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Peptic Ulcers (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Peptic Ulcers Overview 7 Therapeutics Development 8 Pipeline Products for Peptic Ulcers - Overview 8 Peptic Ulcers - Therapeutics under Development by Companies 9 Peptic Ulcers - Pipeline Products Glance 10 Clinical Stage Products 10 Early Stage Products 11 Peptic Ulcers - Products under Development by Companies 12 Peptic Ulcers - Companies Involved in Therapeutics Development 13 Astellas Pharma Inc 13 Boryung Pharmaceutical Co Ltd 14 ChoDang Pharm Co Ltd 15 Daewoong Pharmaceutical Co Ltd 16 Kukje Pharmaceutical Industry Co Ltd 17 RaQualia Pharma Inc 18 Sequella Inc 19 Sinil Pharmaceutical Co Ltd 20 XuanZhu Pharma Co Ltd 21 Yooyoung Pharmaceutical Co Ltd 22 Peptic Ulcers - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Combination Products 24 Assessment by Target 25 Assessment by Mechanism of Action 27 Assessment by Route of Administration 29 Assessment by Molecule Type 30 Drug Profiles 31 (ecabet + ranitidine) - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 (lansoprazole + omeprazole) - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 anaprazole sodium - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 ASP-6537 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 BGC-001 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 cholesteryl glucoside - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 DWJ-1386 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 DWJ-206 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 KJ-14001 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 PMKS-005 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 RQ-00000774 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 SI-001002 SR - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Small Molecule to Inhibit Potassium Transporting ATPase Alpha Chain 1 Inhibitor for Peptic Ulcers and Reflux Esophagitis - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Small Molecules for Gastric Ulcers - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 SQ-109 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 YYD-601 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 Peptic Ulcers - Dormant Projects 49 Peptic Ulcers - Discontinued Products 51 Peptic Ulcers - Product Development Milestones 52 Featured News & Press Releases 52 Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies 52 Dec 06, 2010: Sequella Wins FDA Approval To Begin Phase II Trial Of SQ109 In Helicobacter pylori-Associated Duodenal Ulcers 53 Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck 53 Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations 54 Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy 54 Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc. 55 Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium) 55 Jun 01, 2007: AstraZeneca's Prilosec Patents Upheld By Court 56 Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court 56 Appendix 57 Methodology 57 Coverage 57 Secondary Research 57 Primary Research 57 Expert Panel Validation 57 Contact Us 57 Disclaimer 58
List of Tables
Number of Products under Development for Peptic Ulcers, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Comparative Analysis by Clinical Stage Development, H2 2016 10 Comparative Analysis by Early Stage Development, H2 2016 11 Products under Development by Companies, H2 2016 12 Peptic Ulcers - Pipeline by Astellas Pharma Inc, H2 2016 13 Peptic Ulcers - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2016 14 Peptic Ulcers - Pipeline by ChoDang Pharm Co Ltd, H2 2016 15 Peptic Ulcers - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016 16 Peptic Ulcers - Pipeline by Kukje Pharmaceutical Industry Co Ltd, H2 2016 17 Peptic Ulcers - Pipeline by RaQualia Pharma Inc, H2 2016 18 Peptic Ulcers - Pipeline by Sequella Inc, H2 2016 19 Peptic Ulcers - Pipeline by Sinil Pharmaceutical Co Ltd, H2 2016 20 Peptic Ulcers - Pipeline by XuanZhu Pharma Co Ltd, H2 2016 21 Peptic Ulcers - Pipeline by Yooyoung Pharmaceutical Co Ltd, H2 2016 22 Assessment by Monotherapy Products, H2 2016 23 Assessment by Combination Products, H2 2016 24 Number of Products by Stage and Target, H2 2016 26 Number of Products by Stage and Mechanism of Action, H2 2016 28 Number of Products by Stage and Route of Administration, H2 2016 29 Number of Products by Stage and Molecule Type, H2 2016 30 Peptic Ulcers - Dormant Projects, H2 2016 49 Peptic Ulcers - Dormant Projects (Contd..1), H2 2016 50 Peptic Ulcers - Discontinued Products, H2 2016 51



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify